You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Displaying Drugs List

14 Items
Other Name(s): Xeloda® (multiple brands available)
Funding:
ODB Limited Use
  • capecitabine - As part of the CAPOX (XELOX) regimen for the first-line and second-line treatment of metastatic colorectal, small bowel or appendiceal adenocarcinomas.
  • capecitabine - For adjuvant treatment of stage 3 or high risk stage 2* colon, small bowel or appendiceal adenocarcinomas in patients who have completed surgery (within three months), who would normally be candidates for adjuvant chemotherapy with 5FU/LV.
  • capecitabine - First-line treatment of patients with metastatic colorectal, small bowel and appendiceal adenocarcinomas in whom combination chemotherapy is not recommended.
  • capecitabine - Treatment of metastatic breast cancer where patients have progressed after prior chemotherapy
  • capecitabine - In combination with trastuzumab and cisplatin for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease
  • capecitabine - Neo-adjuvant treatment of rectal cancer
  • capecitabine - In combination with a platinum-containing product and epirubicin for the treatment of advanced (non-resectable; either locally advanced or metastatic) gastric or gastro-esophageal junction cancer
  • capecitabine - As part of the CAPOX (XELOX) regimen for the treatment of adjuvant stage III and high risk stage II colorectal, small bowel or appendiceal adenocarcinomas.
Dec 2016
Other Name(s): Paraplatin AQ® (multiple brands available)
Aug 2016
Other Name(s): Erbitux® (Imclone)
Funding:
New Drug Funding Program
  • Cetuximab and Radiation - Locally Advanced Squamous Cell Carcinoma of the Head and Neck
  • Cetuximab with Irinotecan - Third Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Jun 2017
Other Name(s): Platinol AQ® (multiple brands available)
Aug 2016
Other Name(s): Procytox® (Baxter)
Funding:
ODB - General Benefit
  • cyclophosphamide - oral tablets
Nov 2017
Other Name(s): Taxotere® (multiple brands available)
Funding:
New Drug Funding Program
  • Docetaxel - Metastatic Castration-Resistant Prostate Cancer
  • Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
  • Docetaxel - Non-Small Cell Lung Cancer (Second or Subsequent Line)
  • Docetaxel - Neoadjuvant treatment for Non-Metastatic Breast Cancer
  • Docetaxel - Metastatic Breast Cancer
  • Docetaxel - Hormone Sensitive Prostate Cancer
  • Trastuzumab with First Line Docetaxel - Metastatic Breast Cancer
  • Docetaxel - CYCLDOCE for Early Operable Breast Cancer
  • Docetaxel - FEC-D or AC-DOCE for Adjuvant Treatment for Breast Cancer
Nov 2017
Other Name(s): Adriamycin PFS® (multiple brands available)
Nov 2017
Other Name(s): Tarceva® (Hoffmann-LaRoche)
Funding:
Exceptional Access Program
  • erlotinib - Incurable progressive NSCLC, with specific criteria
May 2017
Other Name(s): Adrucil® (multiple brands available); Efudex® Cream (Valeant)
Aug 2016
Other Name(s): Iressa® (AstraZeneca)
Funding:
Exceptional Access Program
  • gefitinib - First-line monotherapy in locally advanced (not amenable to curative therapy) or metastatic NSCLC patients who have activating mutations of EGFR-TK, with specific criteria
Aug 2016
Other Name(s): Gemzar® (multiple brands available)
Funding:
New Drug Funding Program
  • Gemcitabine - Carcinoma of Bladder or Urothelium
  • Gemcitabine - Non-Small Cell Lung Cancer (NSCLC)
  • Gemcitabine - Advanced Pancreatic Cancer
Updated
Feb 2018
Funding:
ODB - General Benefit
  • methotrexate - oral tablets
Dec 2017